SCHEMBL5523563

SCHEMBL5523563

CCOCC(=O)NC(CC(=O)NCC#N)C1CCCCC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSK P43235 6/20 0.39
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CTSL P07711 4/20 0.38
CTSS P25774 5/20 0.37
CTSB P07858 4/20 0.34
DPP4 P27487 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
TSHR P16473 1/20 0.32
USP2 O75604 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KDM4E B2RXH2 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5523195 0.80 CTSK (0.42) CTSKCTSLCTSSCTSBDPP4
SCHEMBL5528435 0.79 EPHX1 (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2CTSL
SCHEMBL5523597 0.77 CTSK (0.40) CTSKALDH1A1SMN1; SMN2CTSLCTSS
SCHEMBL5530341 0.75 EPHX1 (0.51) TSHR
SCHEMBL5520605 0.75 EPHX2 (0.57) CTSKALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5528503 0.75 ALDH1A1 (0.42) CTSKALDH1A1NPC1RAB9ACTSL
SCHEMBL5523552 0.75 CTSS (0.63) CTSKCTSLCTSSCTSB
SCHEMBL5523555 0.75 CTSS (0.63) CTSKCTSLCTSSCTSB
SCHEMBL5523564 0.74 CTSK (0.39) CTSKCTSLCTSSCTSBDPP4
SCHEMBL5524219 0.74 HIF1A (0.47) ALDH1A1SMN1; SMN2CTSLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2007-01-18 US disclosed
US-20040147745-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2004-07-29 US disclosed
EP-1178958-B1 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2004-02-18 EP disclosed
US-20030096796-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-05-22 US disclosed
US-6455502-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-09-24 US disclosed
EP-1178958-A2 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-02-13 EP disclosed
WO-2000055125-A2 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096796-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 CTSK 32/4885ALDH1A1 4049/4885NPC1 545/4885
US-20040147745-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 CTSK 32/4885ALDH1A1 4049/4885NPC1 545/4885
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS CTRL, SERPINB1, CPN1 CTSK 32/4885ALDH1A1 4049/4885NPC1 545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.